Search for a clinical trial
Other search option(s)
10 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
SUMIT: A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (Phase III) - FR
Institution: Information not provided - FR
FRANCE
PAYS DE LA LOIRE
ANGERS
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer (Phase III) - FR
CHU d'Angers
Département d'endocrinologie, diabétologie et nutrition
GERMANY
Baden-Württemberg
HEIDELBERG
SUMIT: A Randomised, double-blind study to assess the efficacy of Selumetinib (AZD6244: ARRY-142886) in combination with Dacarbazine compared with Placebo in combination with Dacarbazine as first systemic therapy in patients with Metastatic Uveal Melanoma - DE - Completed
Universitätsklinikum Heidelberg
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer (Phase III) -DE-
Institution: Information not provided - DE
SPAIN
Cataluña
BARCELONA
A randomized, open-label, national multicenter, phase III trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous hematopoietic stem cell transplant in patients with newly-diagnosed, symptomatic multiple myeloma - ES (completed)
Hospital Clínic de Barcelona
Servicio de Hematología
SPAIN
Cataluña
L'HOSPITALET DE LLOBREGAT
SUMIT: A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma - ES (terminated)
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Oncología Médica
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
(ASTRA) Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer - SE
Institution: Information not provided - SE
UNITED KINGDOM
Greater London
LONDON
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
UNITED KINGDOM
Greater London
NORTHWOOD
SUMIT: A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma - UK
Mount Vernon Hospital
Mount Vernon Cancer Centre
UNITED KINGDOM
Tyne & Wear
NEWCASTLE UPON TYNE